Oral medications are being increasingly used to treat patients with lymphoma and chronic lymphocytic leukemia (CLL). Five oral drugs have been approved over the past three years for eight different indications in lymphoma and CLL. Many patients report numerous advantages…
LRF Scientific Advisory Board Members to be Joined by Current and Former Grantees at the 59th ASH Annual Meeting & Exposition New York, NY (December 7, 2017) –The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively…
Findings from the 2015 Lymphoma Research Foundation scientific symposium on adolescent/young adult (AYA) lymphomas have been published int he influential journal Blood Advances. The paper, “Adolescent and Young Adult Lymphoma: Collaborative Efforts at Understanding Biology and Optimizing Care,” reviews lymphoma…
The Nation’s Premier Lymphoma-Specific Research Organization Also Adds Four Experts to Industry Leading SAB New York, NY (July 1, 2017) – The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and…
Applications for 2018 research grants are now open and will be accepted until September The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive…
By: Ann LaCasce, MD and Sonali M. Smith, MD The last decade has seen a number of exciting developments in lymphoma research, with new therapies, improved treatment strategies, and a more developed understanding of lymphoma biology improving patient treatment and…
Hans-Guido Wendel, MD (Memorial Sloan Kettering Cancer Center) is a two-time recipient of the Lymphoma Research Foundation’s Follicular Pathways Grant, and a member of LRF’s Scientific Advisory Board. As befits the grant name, Dr. Wendel’s research focuses on the microbiology…
Science Translational Medicine report led by Lymphoma Research Foundation Scientific Advisory Board members and LRF Grantees As personalized medicine becomes increasingly popular, researchers continue to discover ways to ensure that the right patient receives the right treatment at the right…
The Annual Meeting of the American Society of Hematology (ASH), convened in December 2014, highlighted the expanding array of novel therapy treatments showing promise for non-Hodgkin lymphoma (NHL) patients. Covering a gamut of research from expanded analyses of recently approved…